OliPass

OliPass Interest Coverage

The Interest Coverage Ratio of OliPass (244460.KQ) as of Oct 22, 2026 is -13.10. In the previous year, Interest Coverage Ratio was -321.70 — a change of -95.93% (higher).

Interest Coverage

-13.10

YoY

-95.93%

Last updated:

Interest Coverage Ratio of OliPass is 2024 -13.10 . Interest Coverage Ratio of OliPass was 2023 -321.70 . It decreases by -95.93% higher compared to the previous year.

The OliPass Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-0.48 KRW
Jan 1, 2018
-3.70 KRW
Jan 1, 2019
-0.91 KRW
Jan 1, 2020
-691.36 KRW
Jan 1, 2021
-40.11 KRW
Jan 1, 2022
-90.82 KRW
Jan 1, 2023
-321.70 KRW
Jan 1, 2024
-13.10 KRW
The OliPass Interest Coverage history
YEARInterest CoverageYoY
-13.10-95.93%
-321.70+254.22%
-90.82+126.42%
-40.11-94.20%
-691.36+75,618.71%
-0.91-75.31%
-3.70+663.70%
-0.48+62.29%
-0.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OliPass Stock analysis

What does OliPass do? OliPass Corp develops and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, and cancer immunotherapy medicine. The company also researches, develops, and sells functional cosmetics using artificial gene platform technology. Its primary customers are healthcare providers and pharmaceutical companies seeking innovative treatments and cosmetic solutions. OliPass Corp generates revenue through the sale of these medical products and functional cosmetics, focusing on biotechnology-driven healthcare and beauty markets. The company's product portfolio includes nonopioid analgesics for pain management, hyperlipidemia medicines for cholesterol control, ocular angiogenesis inhibitors for eye conditions, duchenne dystrophy treatments, and cancer immunotherapy medicines. Functional cosmetics developed via artificial gene platform technology target consumers interested in advanced skincare. OliPass Corp's revenue streams are derived from direct sales to healthcare institutions and pharmaceutical distributors, with a strong emphasis on biotech innovation in both medicine and cosmetics. OliPass Corp's business model centers on developing proprietary biological products through research and development. The firm sells its medicines and functional cosmetics to healthcare providers and pharmaceutical companies, leveraging its artificial gene platform technology for product differentiation. Revenue is generated through the commercialization of its medical and cosmetic product lines, which cater to specific health and beauty segments requiring advanced biotechnological solutions. OliPass is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OliPass stock

Interest Coverage Ratio of OliPass is -13.10 in 2024.

Interest Coverage Ratio of OliPass changed from -321.70 to -13.10, representing a -95.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio OliPass since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's OliPass with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — OliPass

All Key Metrics — OliPass